Literature DB >> 27246524

Specific T cells for the treatment of cytomegalovirus and/or adenovirus in the context of hematopoietic stem cell transplantation.

Rita Creidy1, Despina Moshous2, Fabien Touzot3, Caroline Elie4, Bénédicte Neven2, Aurélie Gabrion1, Marianne Leruez-Ville5, Sébastien Maury6, Brigitte Ternaux1, Jennifer Nisoy1, Jean-Marc Luby1, Sébastien Héritier7, Jean-Hugues Dalle8, Marie Ouachée-Chardin9, Aliénor Xhaard10, Xavier Thomas11, Patrice Chevallier12, Laetitia Souchet13, Jean-Marc Treluyer4, Capucine Picard14, Salima Hacein-Bey-Abina15, Liliane Dal Cortivo1, Stéphane Blanche16, Marina Cavazzana17.   

Abstract

Mesh:

Year:  2016        PMID: 27246524     DOI: 10.1016/j.jaci.2016.03.032

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  12 in total

1.  Adoptive T-cell therapy for pediatric cytomegalovirus-associated retinitis.

Authors:  Shiney Seo; Corey Smith; Christopher Fraser; Rajan Patheja; Shaheen P Shah; Sweera Rehan; Pauline Crooks; Michelle A Neller; Rajiv Khanna
Journal:  Blood Adv       Date:  2019-06-11

Review 2.  Virus-Specific T Cells: Current and Future Use in Primary Immunodeficiency Disorders.

Authors:  Katherine M Harris; Blachy J Davila; Catherine M Bollard; Michael D Keller
Journal:  J Allergy Clin Immunol Pract       Date:  2018-12-21

3.  T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy.

Authors:  Michael D Keller; Sam Darko; Haili Lang; Amy Ransier; Christopher A Lazarski; Yunfei Wang; Patrick J Hanley; Blachy J Davila; Jennifer R Heimall; Richard F Ambinder; A John Barrett; Cliona M Rooney; Helen E Heslop; Daniel C Douek; Catherine M Bollard
Journal:  Br J Haematol       Date:  2019-06-20       Impact factor: 6.998

Review 4.  Viral-specific T-cell transfer from HSCT donor for the treatment of viral infections or diseases after HSCT.

Authors:  C Qian; Y Wang; L Reppel; M D'aveni; A Campidelli; V Decot; D Bensoussan
Journal:  Bone Marrow Transplant       Date:  2017-10-23       Impact factor: 5.483

Review 5.  Adoptive T Cell Immunotherapy for Patients with Primary Immunodeficiency Disorders.

Authors:  Lauren P McLaughlin; Catherine M Bollard; Michael Keller
Journal:  Curr Allergy Asthma Rep       Date:  2017-01       Impact factor: 4.919

6.  Curative or pre-emptive adenovirus-specific T cell transfer from matched unrelated or third party haploidentical donors after HSCT, including UCB transplantations: a successful phase I/II multicenter clinical trial.

Authors:  Chongsheng Qian; Arnaud Campidelli; Yingying Wang; Huili Cai; Véronique Venard; Hélène Jeulin; Jean Hugues Dalle; Cécile Pochon; Maud D'aveni; Benedicte Bruno; Catherine Paillard; Stéphane Vigouroux; Charlotte Jubert; Patrice Ceballos; Aude Marie-Cardine; Claire Galambrun; Clément Cholle; Isabelle Clerc Urmes; Nadine Petitpain; Marcelo De Carvalho Bittencourt; Véronique Decot; Loïc Reppel; Alexandra Salmon; Laurence Clement; Danièle Bensoussan
Journal:  J Hematol Oncol       Date:  2017-05-08       Impact factor: 17.388

Review 7.  Concise Review: Boosting T-Cell Reconstitution Following Allogeneic Transplantation-Current Concepts and Future Perspectives.

Authors:  Laura Simons; Marina Cavazzana; Isabelle André
Journal:  Stem Cells Transl Med       Date:  2019-03-18       Impact factor: 6.940

8.  In Vitro Expansion of Anti-viral T Cells from Cord Blood by Accelerated Co-cultured Dendritic Cells.

Authors:  Klaudia Kuranda; Sophie Caillat-Zucman; Sylvaine You; Roberto Mallone
Journal:  Mol Ther Methods Clin Dev       Date:  2018-12-31       Impact factor: 6.698

Review 9.  Immune Reconstitution after Haploidentical Donor and Umbilical Cord Blood Allogeneic Hematopoietic Cell Transplantation.

Authors:  Hany Elmariah; Claudio G Brunstein; Nelli Bejanyan
Journal:  Life (Basel)       Date:  2021-01-29

Review 10.  Virus-specific T-cell therapies for patients with primary immune deficiency.

Authors:  Michael D Keller; Catherine M Bollard
Journal:  Blood       Date:  2020-02-27       Impact factor: 25.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.